Ventyx Biosciences (VTYX) announced results from its Phase 2 study of oral, once-daily VTX3232 in patients with Obesity and Cardiovascular Risk Factors. The 175- participant study examined VTX3232 ...
(RTTNews) - Shares of Ventyx Biosciences Inc. (VTYX) skyrocketed over 83% in after-hours trading on Wednesday after the company announced positive results from its Phase 2 study of VTX3232, an oral, ...
(RTTNews) - Ventyx Biosciences, Inc. (VTYX) announced Tuesday positive top-line results from its Phase 2a study of VTX3232, a novel, CNS-penetrant NLRP3 inhibitor, in patients with early-stage ...
Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous system (CNS)-penetrant NLRP3 inhibitor, VTX3232, in individuals with ...
Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232 in patients with obesity and cardiovascular risk factors. What ...
SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a ...
ENCINITAS, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- ...
Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease. The clinical-stage biotech company said the study ...
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a ...
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...
Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now. On October 22, Ventyx Biosciences announced positive topline results from its Phase 2 study of the oral, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback